Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Status:
Completed
Trial end date:
2016-11-11
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of treatment with evolocumab, compared with
placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization
for unstable angina, or coronary revascularization, whichever occurs first, in patients with
clinically evident cardiovascular disease.